Platelet reactivity and thrombogenicity in postmenopausal women

Anand Singla, Kevin P. Bliden, Young Hoon Jeong, Katrina Abadilla, Mark J. Antonino, William C. Muse, Denny P. Mathew, Oscar Bailon, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticlepeer-review


Objective: Age-adjusted incidence of cardiovascular disease, including myocardial infarction, is significantly lower in premenopausal women than in men, which is thought to be caused by the cardioprotective effects of estrogen. However, there is a consistent increase in the incidence of coronary artery disease in postmenopausal women in comparison with premenopausal women. The protective benefit of hormone therapy has not been observed in postmenopausal women. It is unknown whether measures of platelet reactivity and clot strength contribute to the disproportionate incidence of cardiovascular disease between premenopausal and postmenopausal women. Methods: Fifty healthy volunteers, including 25 premenopausal women and 25 postmenopausal women, aged between 40 and 65 years were enrolled. Total estradiol and follicle-stimulating hormone levels were measured for confirmation of menopausal state and comparison testing. Platelet reactivity was assessed using light transmission aggregometry and P-selectin, and glycoprotein IIb/IIIa receptor expression was assessed using flow cytometry. Thrombelastography was used to measure clot strength, clotting time, and fibrinogen activity. Serum cholesterol, C-reactive protein, complete blood count, and comprehensive metabolic panel were also measured. Results: Platelet reactivity did not differ among menopausal states or hormone levels. Clotting time was increased in postmenopausal women (6.6 ± 2.0 vs 7.8 ± 1.2 min, P = 0.013) and significantly correlated with estradiol levels (r = 0.68, P < 0.001). A significantly higher low-density lipoprotein cholesterol level was observed in postmenopausal women (P = 0.05). Mean C-reactive protein levels were numerically higher in the postmenopausal group. Conclusions: The thrombotic risk profile between premenopausal and postmenopausal women is similar. However, improved management of cholesterol may be of clinical benefit. Large-scale studies are required to validate these findings.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
Issue number1
StatePublished - Jan 1 2013


  • Coronary artery disease
  • Menopause
  • Platelet reactivity
  • Thrombogenicity

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Platelet reactivity and thrombogenicity in postmenopausal women'. Together they form a unique fingerprint.

Cite this